Zacks Investment Research upgraded shares of Yield10 Bioscience (NASDAQ:YTEN) from a sell rating to a hold rating in a research report released on Sunday morning, Zacks.com reports.

According to Zacks, “Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. “

Other equities analysts have also issued reports about the stock. Maxim Group reissued a buy rating and issued a $3.00 target price on shares of Yield10 Bioscience in a report on Friday, May 31st. National Securities reaffirmed a buy rating and set a $5.00 price target on shares of Yield10 Bioscience in a report on Tuesday, August 20th. Finally, Aegis reiterated a buy rating and set a $2.00 price target on shares of Yield10 Bioscience in a research report on Tuesday, August 13th.

NASDAQ:YTEN opened at $0.64 on Friday. The stock has a fifty day moving average price of $0.87 and a 200-day moving average price of $1.00. The company has a market cap of $8.01 million, a price-to-earnings ratio of -0.70 and a beta of 3.05. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.33 and a current ratio of 3.33. Yield10 Bioscience has a fifty-two week low of $0.60 and a fifty-two week high of $1.77.

Yield10 Bioscience (NASDAQ:YTEN) last posted its quarterly earnings results on Monday, August 12th. The specialty chemicals company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.06. Yield10 Bioscience had a negative return on equity of 145.61% and a negative net margin of 1,320.21%. The business had revenue of $0.32 million during the quarter. Research analysts predict that Yield10 Bioscience will post -0.66 EPS for the current fiscal year.

A hedge fund recently raised its stake in Yield10 Bioscience stock. Renaissance Technologies LLC boosted its holdings in Yield10 Bioscience Inc (NASDAQ:YTEN) by 9.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 478,176 shares of the specialty chemicals company’s stock after buying an additional 41,500 shares during the quarter. Renaissance Technologies LLC owned approximately 3.83% of Yield10 Bioscience worth $463,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 7.69% of the company’s stock.

About Yield10 Bioscience

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.

See Also: Understanding Specialty Certificates of Deposit

Get a free copy of the Zacks research report on Yield10 Bioscience (YTEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.